OncoMatch/Clinical Trials/Brain Cancer — Glioblastoma (GBM)
Brain Cancer — Glioblastoma (GBM) Clinical Trials
OncoMatch filters Brain Cancer — Glioblastoma (GBM) trials by the molecular markers that determine eligibility — IDH1, IDH2, EGFR, MGMT, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Brain Cancer — Glioblastoma (GBM) trials
These are the molecular markers most commonly required or evaluated in Brain Cancer — Glioblastoma (GBM) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Brain Cancer — Glioblastoma (GBM) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Children's Oncology Group
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Jazz Pharmaceuticals
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Global Coalition for Adaptive Research
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Nuvation Bio Inc.
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NovoCure GmbH
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Ivy Brain Tumor Center
How OncoMatch finds Brain Cancer — Glioblastoma (GBM) trials for you
AI reads the protocol
Every Brain Cancer — Glioblastoma (GBM) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Brain Cancer — Glioblastoma (GBM) and mark your biomarker results — IDH1, IDH2, EGFR — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.